The FDA approved risankizumab for patients with Crohn's disease in June.
In the coming years, clinicians may be able to better prescribe targeted treatments for patients with inflammatory bowel disease (IBD).
With June’s US Food and Drug Administration’s (FDA) approval of risankizumab (SKYRIZI) for patients with Crohn's disease, the first interleukin-23 (IL-23) medication approved, the next wave of IBD drugs may focus on this specific cytokine.
In the latest episode of DocTalk, Marla Dubinsky, MD, chief, division of pediatric gastroenterology for the Mount Sinai Health System, co-director of the Susan and Leonard Feinstein IBD Center at Mount Sinai talks about why this approval may pave the way for better treatments for IBD and why IL-23 is a promising class on its own.
“My sort of role for the next five years is to scream from the rooftops the idea that if you have a patient who has a family history of an IL-23 disease, please use 23 If you can,” she said.
Dubinsky has long been a proponent using this type of drug for patients with IBD.